The essence of our business model is to intercept 'orphan' or 'orphan-like' drugs at a late stage of clinical development in order to take full advantage of shorter development timelines, regulatory incentives, and the curtailment of risk We are in the process of building a unique business model without precedent in the Japanese pharmaceutical industry.
Success in identifying value-added drug candidates from a global network with the highest potential.
1.pharmaceuticals previously approved
2.drug candidates in late-stage clinical
testing (approaching POC)
3.drug candidates likely to receive
'Orphan' designation by the
Possessing extraordinary capabilities for evaluating research outcomes, supported by the sound judgment of our Scientific Advisory Board (SAB) and business/clinical development teams.
Completing the "Value Chain" of our business model through professional market research aimed at identifying clinical needs, effective promotion of launched products, and completion of all necessary post-market surveys.
Superior negotiating capabilities with foreign bio-ventures, enabling the in-licensing or collaborative development of only the best drug candidates
Extensive know-how in clinical development due to the clinical development team's wealth of pharmaceutical experience.
Through close collaboration and the utilization of bridging strategies, late-stage drug candidates licensed in from bio-ventures in the EU/US enjoy much shorter clinical development timelines in attaining marketing approval.
Through strong collaborative and partnering efforts with global bio-ventures involved in drug discovery, preclinical/clinical development, and marketing/manufacturing, SymBio has established a ‘pool' of prime drug candidates for the Japanese market.